Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Scil Technology Announces Positive Results in Preclinical Proof-of-Concept Study in Spinal Fusion

ST01 is an innovative, ceramic based, fully synthetic osteoinductive, biodegradable bone graft substitute activated by a recombinant human bone morphogenic protein (BMP) variant. The product is in development for lumbar, thoracic and cervical spinal fusion and related procedures. By using its proprietary coating technology the biomaterial is homogenously coated with the growth factor, allowing an improved bioavailability and a longer dwelling time of the protein at the implantation site compared to competitor products. The protein is released from the carrier over a period of more than seven days in a highly controlled manner, which represents an important feature for safety aspects of the product.
The ceramic β-TCP based biomaterial is an appropriate matrix for BMP due to its superior biomechanical properties. The product is compression-resistant, able to withstand mechanical pressure of soft tissue enclosing the implantation side and perfectly meets the needs of orthopaedic surgeons .
Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“Scil Technology has now established itself as a leading company in regenerative bone therapies. We plan to build on this study with further preclinical investigations.”

About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, bone trauma, joint cartilage defects and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.
For more information please visit:

Publisher Contact Information:

Scil Technology GmbH
+49 (0) 89 8565 1824

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jan 10€20.0MBusiness applications
Jan 10€20.0MBiotechnology
Jan 10€13.5MArtificial Intelligence
Jan 9€4.0MSoftware development
Jan 9N/AInternet services
Jan 9€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.